Legal Opinion
Leavitt v. Alnylam Pharm., Inc.
District Court, District of Columbia
Decided May 8, 2019No. Civil Action No. 18-12433-NMGPublishedCited by 2 opinions
1Opinion of the CourtGorton, J.
This putative securities fraud class action is brought by Caryl Hull Leavitt ("Leavitt") on behalf of herself and other *63similarly situated investors against Alnylam Pharmaceuticals, Inc., its Chief Executive Officer and its Chief Financial Officer (collectively "Alnylam", "the Company" or "defendants"). Leavitt alleges that defendants made false and/or misleading statements regarding the efficacy and marketability of its therapeutic injection for the treatment of hereditary ATTR amyloidosis during the class period.
Leavitt bring this putative class action pursuant to the Private Securities…
2Cases cited5 opinions
- Dura Pharmaceuticals, Inc. v. BroudoSupreme Court of the United States · 2005
- In Re Olsten Corp. Securities Litig.District Court, E.D. New York · 1998
- In Re Lernout & Hauspie Securities LitigationDistrict Court, D. Massachusetts · 2001
- Arkansas Teacher Retirement System v. Insulet Corp.District Court, D. Massachusetts · 2016
- Soto v. HenslerDistrict Court, D. Delaware · 2017
3Cited by2 opinions
- Elas v. PrinceDistrict Court, D. Massachusetts · 2024
- Luongo v. Desktop Metal, Inc.District Court, D. Massachusetts · 2022